Abstract:Spinocerebellar ataxia type 2 (SCA2) is caused by triple nucleotide repeat (CAG) expansion in the coding region of the ATAXN2 gene on chromosome 12, which produces an elongated, toxic polyglutamine tract, leading to Purkinje cell loss. There is currently no effective therapy. One of the main obstacles that hampers therapeutic development is lack of an ideal disease model. In this study, we have generated and characterized SCA2-induced pluripotent stem (iPS) cell lines as an in vitro cell model. Dermal fibroblasts (FBs) were harvested from primary cultures of skin explants obtained from a SCA2 subject and a healthy subject. For reprogramming, hOct4, hSox2, hKlf4, and hc-Myc were transduced to passage-3 FBs by retroviral infection. Both SCA2 iPS and control iPS cells were successfully generated and showed typical stem cell growth patterns with normal karyotype. All iPS cell lines expressed stem cell markers and differentiated in vitro into cells from three embryonic germ layers. Upon in vitro neural differentiation, SCA2 iPS cells showed abnormality in neural rosette formation but successfully differentiated into neural stem cells (NSCs) and subsequent neural cells. SCA2 and normal FBs showed a comparable level of ataxin-2 expression; whereas SCA2 NSCs showed less ataxin-2 expression than normal NSCs and SCA2 FBs. Within the neural lineage, neurons had the most abundant expression of ataxin-2. Time-lapsed neural growth assay indicated terminally differentiated SCA2 neural cells were short-lived compared with control neural cells. The expanded CAG repeats of SCA2 were stable throughout reprogramming and neural differentiation. In conclusion, we have established the first disease-specific human SCA2 iPS cell line. These mutant iPS cells have the potential for neural differentiation. These differentiated neural cells harboring mutations are invaluable for the study of SCA2 pathogenesis and therapeutic drug development.

Human Stem Cell Models of Polyglutamine Diseases: Sources for Disease Models and Cell Therapy

Induced Pluripotent Stem Cells: Ex Vivo Models for Human Diseases Due to Mitochondrial DNA Mutations

Stem Cells for the Treatment of Neurodegenerative Diseases

Patient-specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases.

Generation of Human-Induced Pluripotent Stem Cells to Model Spinocerebellar Ataxia Type 2 in Vitro

Use of human stem cells in Huntington disease modeling and translational research

Human-induced pluripotent stem cells: potential for neurodegenerative diseases

A perspective on human cell models for POLG-spectrum disorders: advantages and disadvantages of CRISPR-Cas-based vs. patient-derived iPSC models

Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation

Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery

Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases

Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases

Human cellular models of medium spiny neuron development and Huntington disease

Neuromuscular Organoids Model Spinal Neuromuscular Pathologies in C9orf72 Amyotrophic Lateral Sclerosis

Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders

Modeling Human Neurological and Neurodegenerative Diseases: From Induced Pluripotent Stem Cells to Neuronal Differentiation and Its Applications in Neurotrauma

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Induced Pluripotent Stem Cells and Neurodegenerative Diseases

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Alleviating Neurodegeneration in Drosophila Models of PolyQ Diseases